Literature DB >> 27637357

Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action.

Peter V Danenberg1, Bengt Gustavsson2, Patrick Johnston3, Per Lindberg4, Rudolf Moser5, Elisabeth Odin2, Godefridus J Peters6, Nicholas Petrelli7.   

Abstract

Folates have been used with cytotoxic agents for decades and today they are used in hundreds of thousands of patients annually. Folate metabolism is complex. In the treatment of cancer with 5-fluorouracil, the administration of folates mechanistically leads to the formation of [6R]-5,10-methylene-tetrahydrofolate, and the increased concentration of this molecule leads to stabilization of the ternary complex comprising thymidylate synthase, 2'-deoxy-uridine-5'-monophosphate, and [6R]-5,10-methylene-tetrahydrofolate. The latter is the only natural folate that can bind directly in the ternary complex, with other folates requiring metabolic activation. Modulation of thymidylate synthase activity became central in the study of folate/cytotoxic combinations and, despite wide use, research into the folate component was neglected, leaving important questions unanswered. This article revisits the mechanisms of action of folates and evaluates commercially available folate derivatives in the light of current research. Better genomic insight and availability of new analytical techniques and stable folate compounds may open new avenues of research and therapy, ultimately bringing increased clinical benefit to patients.
Copyright © 2016 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  5-Fluorouracil, [6R]-5,10-methylene-tetrahydrofolate; Folate metabolism; Leucovorin; Mechanism of action

Mesh:

Substances:

Year:  2016        PMID: 27637357     DOI: 10.1016/j.critrevonc.2016.08.001

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  10 in total

1.  5-FU-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer.

Authors:  Gyanendra Acharya; Maria T Cruz Carreras; Terry Wynne Rice
Journal:  BMJ Case Rep       Date:  2017-11-21

2.  In Silico Identification of Novel Interactions for FABP5 (Fatty Acid-Binding Protein 5) with Nutraceuticals: Possible Repurposing Approach.

Authors:  Ricardo Cabezas; Amirhossein Sahebkar; Valentina Echeverria; Janneth González Santos; Ghulam Md Ashraf; George E Barreto
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  5-Fluorouracil Neurotoxicity in the Absence of Dihydropyrimidine Dehydrogenase Deficiency Case Report.

Authors:  Rebecca Jules; Arushi Thaper; Ryan Foster; Pouya Ameli; Christopher Robinson; Michael Pizzi; Marc-Alain Babi; Carolina B Maciel; Katharina M Busl; Raju Reddy; William Roth
Journal:  Neurohospitalist       Date:  2022-01-03

4.  Synthesis and Physicochemical Characterization of the One-Carbon Carrier 10-Formyltetrahydrofolate; A Reference Standard for Metabolomics.

Authors:  Anita H Lewin; Peter Silinski; James Hayes; Amanda Gilbert; S Wayne Mascarella; Herbert H Seltzman
Journal:  Metabolomics       Date:  2017-08-31       Impact factor: 4.290

Review 5.  Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users.

Authors:  Fedra Luciano-Mateo; Anna Hernández-Aguilera; Noemi Cabre; Jordi Camps; Salvador Fernández-Arroyo; Jose Lopez-Miranda; Javier A Menendez; Jorge Joven
Journal:  Nutrients       Date:  2017-02-10       Impact factor: 5.717

6.  Relationship between folate concentration and expression of folate-associated genes in tissue and plasma after intraoperative administration of leucovorin in patients with colorectal cancer.

Authors:  Helena Taflin; Elisabeth Odin; Kristoffer Derwinger; Göran Carlsson; Bengt Gustavsson; Yvonne Wettergren
Journal:  Cancer Chemother Pharmacol       Date:  2018-09-29       Impact factor: 3.333

7.  Intratumoral gene expression of dihydrofolate reductase and folylpoly-c-glutamate synthetase affects the sensitivity to 5-fluorouracil in non-small cell lung cancer.

Authors:  Kayo Sakon; Masato Sasaki; Kaede Tanaka; Tae Mizunaga; Keita Yano; Yuuko Kawamura; Akitoshi Okada; Takeshi Ikeda; Sawaka Tanabe; Atsushi Takamori; Narihisa Yamada; Kouichi Morioka; Takaaki Koshiji
Journal:  Discov Oncol       Date:  2021-06-25

Review 8.  One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies.

Authors:  Antonia Kalushkova; Patrick Nylund; Alba Atienza Párraga; Andreas Lennartsson; Helena Jernberg-Wiklund
Journal:  Epigenomes       Date:  2021-10-08

9.  Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin.

Authors:  Helena Taflin; Elisabeth Odin; Göran Carlsson; Roger Tell; Bengt Gustavsson; Yvonne Wettergren
Journal:  Cancer Chemother Pharmacol       Date:  2020-10-24       Impact factor: 3.333

10.  A multiple network-based bioinformatics pipeline for the study of molecular mechanisms in oncological diseases for personalized medicine.

Authors:  Serena Dotolo; Anna Marabotti; Anna Maria Rachiglio; Riziero Esposito Abate; Marco Benedetto; Fortunato Ciardiello; Antonella De Luca; Nicola Normanno; Angelo Facchiano; Roberto Tagliaferri
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.